

Table of Contents

Chapter 1	Regulatory Basics of Process and Design Validation	1
	<i>Robert Falcone, Ph.D., FRAPS, FTOPRA</i>	
Chapter 2	Risk-Based Verification and Validation	7
	<i>John E. Lincoln</i>	
Chapter 3	Gap Assessments for Medical Devices	21
	<i>Brett Hofman, BS, MBA, Courtney Divine, BS, CPP, CSSGB, Heather Valley, MS, RAC-Global, and Timothy Wech, MSE, PE</i>	
Chapter 4	Test Method Validation and How it is Used for Medical Devices and Packaging	33
	<i>Brian K. Farison, Dylan Stover, and John E. Lincoln</i>	
Chapter 5	Design of Experiments	57
	<i>Anthony Carra</i>	
Chapter 6	Sterilization Validation Principles	77
	<i>Gerry O'Dell</i>	
Chapter 7	Six Sigma Concepts in Validation Studies for Medical Device Packaging	95
	<i>Brian K. Farison and Rod Patch</i>	
Chapter 8	Medical Packaging Validation	117
	<i>David DiVaccaro</i>	
Chapter 9	Cleaning Validations of Medical Products.....	125
	<i>Steven G. Richter, PhD</i>	
Chapter 10	Software Validation for Life Sciences.....	135
	<i>Wes Bloemker</i>	
Chapter 11	FDA Unique Device Identification Verification and Validation.....	161
	<i>Jonathan C. Bretz and Jay Crowley</i>	
Chapter 12	Equipment Validation.....	173
	<i>John E. Lincoln</i>	

Chapter 13	Sample Sizes for Verification and Validation.....	187
	<i>Steven Walfish</i>	
Chapter 14	Verification and Validation in Medical Device Computational Modeling and Simulation	201
	<i>Danny L. Levine, PhD, PE</i>	
Chapter 15	Additive (3D Printing) Manufacturing	213
	<i>John E. Lincoln</i>	
Chapter 16	Cybersecurity and Data Integrity	229
	<i>John E. Lincoln</i>	
Chapter 17	Validating the Medical Device Laser-Welding Process	243
	<i>David W. Steinmeier and Lisa Schaller</i>	
Chapter 18	Start-up of Cleanrooms, Initially and After a Worst-Case Event	253
	<i>Jim Polarine and Beth Kroeger-Fahnestock</i>	
Index	261

Figures

Figure 2-1.	FDA Lifecycle	10
Figure 2-2.	Internet FTA Sample Format.....	13
Figure 2-3.	Possible Initial Descriptive Narrative.....	15
Figure 2-4.	Possible Hazard List Format	16
Figure 2-5.	Sample FTA	16
Figure 2-6.	Sample Abbreviated Software FMECA.....	17
Figure 2-7.	Fictitious Final Benefit-Risk Analysis/Statement	18
Figure 2-8.	Incorporating Risk in the V&V Protocol	19
Figure 3-1.	Roles vs. Impact Matrix.....	22
Figure 3-2.	Gap Analysis/Remediation Process Phases	23
Figure 3-3.	Risk Level vs. Gap Size	25
Figure 3-4.	Cascading Effects of Standards Updates	28
Figure 3-5.	Phase-gate Development Process	30
Figure 3-6.	Waterfall Methodology	30
Figure 3-7.	Critical Path Method	30
Figure 3-8.	Hybrid Project Management Methodology Example	31
Figure 3-9.	High-Level Gap Assessment Project Lifecycle	31
Figure 3-10.	Simple Task Board View	31
Figure 3-11.	Burndown Chart	31
Figure 3-12.	Traditional vs. Iterative Planning in a Project Lifecycle	32
Figure 4-1.	Definition of a Test method, ASTM E1488-12(2023)	34
Figure 4-2.	Data Types vs. Resolution.....	35
Figure 4-3.	Process View of Test methods, Peel Test Example.....	37
Figure 4-4.	ISO 11607-1:2019, Section 4.4 Test Methods	41
Figure 4-5.	TMV Waterfall Model (vs. FDA Design Control Guidance Waterfall)	44
Figure 4-6.	Measurement Error, a Comparison of Two “Voices”.....	45
Figure 4-7.	Measurement Error and Decision-Making	46

Figure 4-8.	Precision and “Accuracy”.....	47
Figure 4-9.	Bias and “Accuracy”—Focus on “Bias”.....	48
Figure 4-10.	Precision and Bias.....	49
Figure 4-11.	GRR Tree Diagram, Multi-Vari Chart plus Minitab Statistical Output.....	50
Figure 4-12.	GRR Standard Deviations Explained as Trigonometric Function.....	52
Figure 5-1.	DOE in Process Validation Flow.....	57
Figure 5-2.	Progression of DOE Activities.....	58
Figure 5-3.	Relation of Process Inputs and Outputs.....	59
Figure 5-4.	Minitab ANOVA Analysis Output.....	61
Figure 5-5.	Minitab Example of Design Options.....	62
Figure 5-6.	Minitab Plackett-Burman Design Analysis.....	63
Figure 5-7.	Two-Level Factorial Design Diagram.....	67
Figure 5-8.	Three-Level Factorial Design Diagram.....	67
Figure 5-9.	Minitab Regression Analysis Output.....	68
Figure 5-10.	EVOP Diagram.....	68
Figure 5-11.	Method of Steepest Ascent/Descent.....	68
Figure 5-12.	Central Composite Design Diagram.....	69
Figure 5-13.	Minitab CCD Analysis Output.....	69
Figure 5-14.	Three-Factor Box-Behnken Design Diagram.....	70
Figure 5-15.	Minitab Box-Behnken Analysis Output.....	71
Figure 5-16.	Main Effects Plot.....	71
Figure 5-17.	Interaction Effects Plot.....	71
Figure 5-18.	Screening Minitab Output.....	72
Figure 5-19.	Screening Response Optimizer.....	72
Figure 5-20.	Optimization #1 Main and Interaction Plots.....	72
Figure 5-21.	Optimization #1 Minitab Output.....	73
Figure 5-22.	Optimization #1 Response Optimizer.....	73
Figure 5-23.	Optimization #2 Main and Interaction Plots.....	73
Figure 5-24.	Optimization #2 Contour Plot.....	74
Figure 5-25.	Optimization #2 Response Optimizer.....	74
Figure 5-26.	Capability Analysis Results.....	75
Figure 6-1.	Sterilization Validation.....	78
Figure 7-1.	Six Sigma Process.....	97
Figure 7-2.	GRR Study Structure.....	101
Figure 7-3.	GRR Study Showing Poor Repeatability and Reproducibility.....	102
Figure 7-4.	GRR Study Showing Excellent Repeatability and Reproducibility.....	103
Figure 7-5.	Baseline Process.....	104
Figure 7-6.	Cause-and-Effect Diagram Showing the “6Ms” of Quality: Man, Machine, Measurement, Method, Material, and “Mother Nature”.....	104
Figure 7-7.	Detailed Process Map Example: Sealing Portion of Process.....	105
Figure 7-8.	Three Types of Cause-and-Effect Relationships.....	106
Figure 7-9.	A Process Operating at Full Potential.....	106
Figure 7-10.	Multi-Vari Chart Showing Three Families of Variation: Machine, Cycle, and Tool Cavity.....	108
Figure 7-11.	Main Effects Plots Showing the Effects of Temperature, Time, and Pressure on the Response of Seal Strength (LBF/in).....	109
Figure 7-12.	DOE Interaction Plot Showing the Effects of Pressure on the Response, Seal Strength, at Two Temperature Settings (220°F and 260°F).....	109
Figure 7-13.	Stable Process—Not Capable and Capable.....	110

Figure 7-14. I-MR Chart of Seal Strength by Stage.....	112
Figure 7-15. Waterfall Model (Verification and Validation)	113
Figure 7-16. Traditional PQ Model	113
Figure 7-17. MPQ Approach Model	114
Figure 9-1. Examples of Typical Reusable Medical Devices	125
Figure 9-2. Notebook Studies Can Provide Data to Build Appropriate Validation Activities.....	129
Figure 9-3. Automated Cleaning Equipment Typically Should be Validated Prior to Use	132
Figure 11-1. Organizational Involvement in UDI Implementation.....	164
Figure 11-2. GHTF Process Validation Decision Tree	170
Figure 12-1. The Equipment Verification and Validation Cycle, Simplified	174
Figure 12-2. Application of Design Controls to Waterfall Design Process.....	176
Figure 12-3. Suggested/Possible V&V Test Case/Script Format	181
Figure 12-4. Typical Product Development Milestones With V&V Tasks.....	184
Figure 13-1. Application of Design Controls to Waterfall Design Process.....	188
Figure 13-2. Typical Operating Characteristic Curve (OC)	190
Figure 13-3. Equivalence	192
Figure 14-1. Example of a Discretized Solid Model.....	203
Figure 14-2. Fatigue Test of Femoral Knee Condyle	204
Figure 14-3. Load and Constraint Applied to a Finite Element Model of a Femoral Knee and Maximum Principal Stress in the Implant.....	204
Figure 14-4. Contour Plot of von Mises Equivalent Stress Distribution in a Carotid Artery Wall After Stent Expansion	205
Figure 14-5. Credibility Factors for Modeling and Simulation.....	210
Figure 14-6. Sample Credibility Assessment With Threshold Shown in Dark Gray and Achieved Scores in Light Gray.....	210
Figure 15-1. Additive Manufacturing Process and Related Draft Guidance Sections	216
Figure 17-1. Validation Elements	244
Figure 17-2. Surgical Tool Assembly and Laser Seam Weld.....	245
Figure 17-3. PQ Components.....	246
Figure 17-4. Fixed Input Factors	247
Figure 17-5. Variable Input Factor Range.....	247
Figure 17-6. DoE ANOVA Results.....	248
Figure 17-7. Marginal Means Graph for Burst Pressure.....	248
Figure 17-8. Optimized Laser Welding Parameters.....	249
Figure 17-9. PQ Challenge Laser-Welding Parameters.....	249
Figure 17-10. Weld Location Measurement	250
Figure 17-11. Z-Test Results, PQ Challenge Test.....	250
Figure 18-1. Disinfectant Application Technique	256
Figure 18-2. Triple Cleaning Effectiveness Demonstrated by Viable Particulate Surface Sampling.....	257
Figure 18-3. Cleaning Required for New Build Certification.....	257
Figure 18-4. Example of Pressure Differentials Through an Aseptic Facility.....	258

Tables

Table 3-1.	Gap/Remediation Scope.....	24
Table 3-2.	Scope Change Scenarios.....	24
Table 3-3.	Internal Gaps.....	25
Table 3-4.	External Gaps.....	26
Table 3-5.	ISO 11607-1:2006 vs. ISO 11607-1:2019 Requirements.....	27
Table 4-1.	Required TMV Elements.....	42
Table 4-2.	Basis for 30% GRR Rule; Comparison of Observed to Actual Cp	53
Table 5-1.	Strategy and Selection of Experimental Designs.....	59
Table 5-2.	Design Strategies by Nuisance Factors	60
Table 5-3.	Randomized Block Design	60
Table 5-4.	Plackett–Burman Design.....	63
Table 5-5.	Full Factorial Design	64
Table 5-6.	Temperature Change Effect	65
Table 5-7.	Expanded Design with Interaction Terms.....	65
Table 5-8.	Interaction Effects Calculation Example.....	65
Table 5-9.	Full Factorial Effects Summary	66
Table 5-10.	A Fractional Factorial Design.....	66
Table 6-1.	ISO Sterilization Standards/Guidance Documents.....	78
Table 6-2.	FDA Sterilization Grouping	79
Table 6-3.	Dry Heat IQ.....	81
Table 6-4.	Common OQ Activities.....	83
Table 6-5.	Methods to Establish Sterilization Dose.....	85
Table 6-6.	VD _{max} Methods.....	86
Table 6-7.	Known Defined BIs.....	87
Table 6-8.	Dose Audits.....	91
Table 7-1.	DMAIC Model.....	98
Table 7-2.	DMADV Model	99
Table 7-3.	SIPOC Map.....	100
Table 9-1.	TIR 30 Acceptance Criteria	130
Table 10-1.	Examples of Risk-Based Testing	150
Table 11-1.	UDI Impact on Existing Regulations.....	163
Table 11-2.	62 Attributes for Each Device Identifier	168
Table 13-1.	Statistical Error.....	188
Table 13-2.	CTQ Risk Levels	189
Table 13-3.	K-Values From ISO-16269-6.....	195
Table 13-4.	Noninferiority Sample Sizes.....	197
Table 13-5.	Confidence and Reliability for C=0 Plans	198
Table 14-1.	NASA Modeling and Simulation Risk Matrix.....	209
Table 18-1.	Issues Leading to a Worst–Case Event.....	254

Author Acknowledgments

RAPS and editor, Robert Falcone, PhD, FRAPS, FTOPRA, thank the following subject matter experts for sharing their experience and knowledge and volunteering their time to contribute to this third edition of *Medical Device Validation Handbook*.

Editor

Robert Falcone, PhD, FRAPS,
FTOPRA
Regulatory Manager
Integrated DNA Technologies
IDT

Authors

Wes Bloemker, MBA
Retired

Anthony Carra, MAS, CMQ/
OE, PMP
Owner/Principal Consultant
Business Improvement Group

Jay Crowley, MS
Vice President, Medical
Devices and UDI Practice
Lead
USDM Life Sciences

David W. DiVaccaro, MS
Principal
DiVaccaro Consulting Group,
LLC

Courtney Divine
Senior Packaging Engineer
Network Partners Group

Brian K Farison
Technical Fellow
Network Partners Group

Brett D. Hofman
Senior Packaging Engineer
Network Partners Group

Beth Kroeger-Fahnestock
Director, Biopharma Production
Chemicals, New Product
Introductions
Avantor Sciences

John E. Lincoln
Owner, Principal Consultant
J. E. Lincoln and Associates
LLC

Gerry A. O'Dell, MS, AAMI
Fellow
Owner/President
Gerry O'Dell Consulting

Rod Patch, MBA
Senior Director, Package
Engineering, Product
Labeling & Digital Product
Information
Johnson & Johnson Vision

James N Polarine Jr., MA
Senior Technical Service
Manager
STERIS Corporation

Steven G Richter, PhD, MS,
RAC-US
Senior Regulatory
Microbiologist
Richco Laboratories LLC

Lisa A. Schaller, MS
Director, Quality Assurance
Varian Medical Systems, a
Siemens Healthineers
company

David W. Steinmeier, MBA
Owner
microJoining Solutions

Heather A. Valley, MS,
RAC-Global
Director Regulatory Affairs
Network Partners Group

Steven L Walfish, MBA, MS
Director, Global Technical
Operations Statistics
AstraZeneca

Timothy Wech, MSE, PE
VP, IT and PMO
Network Partners Group